Concise review: Modeling central nervous system diseases using induced pluripotent stem cells

Stem Cells Translational Medicine

Volumn 3, Issue 12, 2014, Pages 1418-1428

  Zeng, Xianmin ^a,b   Hunsberger, Joshua G ^c   Simeonov, Anton ^d   Malik, Nasir ^c   Pei, Ying ^b   Rao, Mahendra ^c,e  

^a XCell Science Inc   (United States)

^b BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e New York Stem Cell Foundation   (United States)

Author keywords

Cell based screening; Central nervous system disease; Genetic engineering; iPSC

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; CELL SCREENING; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE MODEL; DISEASE PREDISPOSITION; DNA ISOLATION; DYSAUTONOMIA; EMBRYONIC STEM CELL; EXPERIMENTAL PARKINSONISM; GENE MUTATION; GENETIC ASSOCIATION; GENOME IMPRINTING; HUMAN; HUNTINGTON CHOREA; KNOCKOUT GENE; MTT ASSAY; NERVOUS SYSTEM INJURY; NEURAL STEM CELL; NONHUMAN; NUCLEAR REPROGRAMMING; PARKINSON DISEASE; PLURIPOTENT STEM CELL; RETT SYNDROME; SCHIZOPHRENIA; SPINAL MUSCULAR ATROPHY; TIME LAPSE IMAGING; XENOGRAFT; BIOLOGICAL MODEL; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DEVELOPMENT; PERSONALIZED MEDICINE; PROCEDURES;

CENTRAL NERVOUS SYSTEM DISEASES; DRUG DISCOVERY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MODELS, NEUROLOGICAL; PRECISION MEDICINE;

EID: 84913531044     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2014-0102     Document Type: Article

References (67)

1. Galvin JE, Ginsberg SD. Expression profiling and pharmacotherapeutic development in thecentral nervoussystem. AlzheimerDis Assoc Disord 2004;18:264–269.
2. Hua JY, Smith SJ. Neural activity and the dynamics of central nervous system development. Nat Neurosci 2004;7:327–332.
3. Lewis MH. Environmental complexity and central nervous system development and function. Ment Retard Dev Disabil Res Rev 2004;10: 91–95.
4. Maier IC, Schwab ME. Sprouting, regeneration and circuit formation in the injured spinal cord: Factors and activity. Philos Trans R Soc Lond B Biol Sci 2006;361:1611–1634.
5. Ricci G, Volpi L, Pasquali L et al. Astrocyte-neuron interactions in neurological disorders. J Biol Phys 2009;35:317–336.
6. Mundy WR, Radio NM, Freudenrich TM. Neuronal models for evaluation of proliferation in vitrousinghighcontentscreening. Toxicology 2010;270:121–130.
7. Vernon H, Clark K, Bressler JP. In vitro models to study the blood brain barrier. Methods Mol Biol 2011;758:153–168.
8. Naik P, Cucullo L. In vitro blood-brain barrier models: Current and perspective technologies. J Pharm Sci 2012;101:1337–1354.
9. Noble M, Mayer-Pröschel M. Growth factors, glia and gliomas. J Neurooncol 1997;35: 193–209.
10. Laustriat D, Gide J, Peschanski M. Human pluripotentstem cellsindrug discoveryandpre-dictive toxicology. Biochem Soc Trans 2010;38: 1051–1057.
11. Mohamet L, Miazga NJ, Ward CM. Familial Alzheimer’s disease modelling using induced pluripotent stem cell technology. World J Stem Cells 2014;6:239–247.
12. Kumar KK, Aboud AA, Bowman AB. The potential of induced pluripotent stem cells as a translational model for neurotoxicological risk. Neurotoxicology 2012;33:518–529.
13. Shtrichman R, Germanguz I, Itskovitz-Eldor J. Induced pluripotent stem cells (iPSCs) derived from different cell sources and their potential for regenerative and personalized medicine. Curr Mol Med 2013; 13:792-805.
14. Liu Y, Rao M. Gene targeting in human pluripotent stem cells. Methods Mol Biol 2011;767:355-367.
15. Giorgetti A, Montserrat N, Rodriguez-Piza I et al. Generation of induced pluripotent stem cells from human cord blood cells with only two factors: Oct4 and Sox2. Nat Protoc 2010;5:811-820.
16. Dowey SN, Huang X, Chou BK et al. Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expression. Nat Protoc 2012;7:2013-2021.
17. Li Y, Li X, Zhao H et al. Efficient induction of pluripotent stem cells from menstrual blood. Stem Cells Dev 2013;22:1147-1158.
18. Merling RK, Sweeney CL, Choi U et al. Transgene-free iPSCs generated from small volume peripheral blood non-mobilized CD34+ cells. Blood 2013;121:e98-e107.
19. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-872.
20. Somers A, Jean JC, Sommer CA et al. Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells 2010;28:1728-1740.
21. Petit I, Kesner NS, Karry R et al. Induced pluripotent stem cells from hair follicles as a cellular. Stem Cell Res (Amst) 2012;8:134-140.
22. Yan X, Qin H, Qu C et al. iPS cells reprog-rammed from human mesenchymal-like stem/progenitor cells of dental tissue origin. Stem Cells Dev 2010;19:469-480.
23. Zhou T, Benda C, Dunzinger S et al. Generation of human induced pluripotent stem cells from urine samples. Nat Protoc 2012;7: 2080-2089.
24. Meske V, Albert F, Wehser R et al. Culture of autopsy-derived fibroblasts as a tool to study systemic alterations in human neurodegenerative disorders such as Alzheimer’s disease— methodological investigations. J Neural Transm 1999;106:537-548.
25. Hjelm BE, Rosenberg JB, Szelinger S et al. Induction of pluripotent stem cells from autopsy donor-derived somatic cells. Neurosci Lett 2011;502:219–224.
26. Bliss LA, Sams MR, Deep-Soboslay A et al. Use of postmortem human dura mater and scalp for deriving human fibroblast cultures. PLoS One 2012;7:e45282.
27. Chamberlain SJ, Li XJ, Lalande M. Induced pluripotent stem (iPS) cells as invitro models of human neurogenetic disorders. Neurogenetics 2008;9:227–235.
28. Paşca SP, Portmann T, Voineagu I et al. Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat Med 2011;17:1657–1662.
29. Song B, Sun G, Herszfeld D et al. Neural differentiation of patient specific iPS cells as a novel approach to study the pathophysiology of multiplesclerosis. Stem Cell Res (Amst) 2012; 8:259–273.
30. Yahata N, Asai M, Kitaoka S et al. Anti-Ab drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer’s disease. PLoS One 2011;6:e25788.
31. Efthymiou A, Shaltouki A, Steiner JP et al. Functional screening assays with neurons generated from pluripotent stem cell-derived neural stem cells. J Biomol Screen 2014;19:32–43.
32. Chambers SM, Fasano CA, Papapetrou EP et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 2009;27: 275–280.
33. Emdad L, D’Souza SL, Kothari HP et al. Efficient differentiation of human embryonic and induced pluripotent stem cells into functional astrocytes. Stem Cells Dev 2012;21:404–410.
34. Liu Q, Pedersen OZ, Peng J et al. Optimizing dopaminergic differentiation of pluripotent stem cells for the manufactureofdopaminergic neurons for transplantation. Cytotherapy 2013; 15:999–1010.
35. Vojnits K, Bremer S. Challenges of using pluripotent stem cells for safety assessments of substances. Toxicology 2010;270:10–17.
36. Miller JD, Ganat YM, Kishinevsky S et al. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 2013;13:691–705.
37. Han Y, Miller A, Mangada J et al. Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopa-mine neurons. PLoS One 2009;4:e7155.
38. Swistowski A, Peng J, Han Y et al. Xeno-free defined conditions for culture of human embryonic stem cells, neural stem cells and do-paminergic neurons derived from them. PLoS One 2009;4:e6233.
39. Egawa N, Kitaoka S, Tsukita K et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med 2012;4: 145-104.
40. Mackay-Sim A. Patient-derived stem cells: Pathways to drug discovery for brain diseases. Front Cell Neurosci 2013;7:29.
41. Haggarty SJ, Perlis RH. Translation: Screening for novel therapeutics with disease-relevant cell types derived from human stem cell models. Biol Psychiatry 2014;75:952–960.
42. Lee G, Papapetrou EP, Kim H et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009;461:402–406.
43. Chambers SM, Qi Y, Mica Y et al. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. NatBio-technol 2012;30:715–720.
44. Amir RE, Van den Veyver IB, Wan M et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999;23:185–188.
45. Marchetto MC, Carromeu C, Acab A et al. A model for neural development and treatment of Rett syndrome using human induced plurip-otent stem cells. Cell 2010;143:527–539.
46. Peng J, Liu Q, Rao MS et al. Using human pluripotent stem cell-derived dopaminergic neurons to evaluate candidate Parkinson’s disease therapeutic agents in MPP+ and rotenone models. J Biomol Screen 2013;18:522–533.
47. An MC, Zhang N, Scott G et al. Genetic correction of Huntington’s disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 2012;11:253–263.
48. Corti S, Nizzardo M, Simone C et al. Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci Transl Med 2012;4:165-162.
49. Xu M, Liu K, Swaroop M et al. d-Tocoph-erol reduces lipid accumulation in Niemann-Pick type C1 and Wolman cholesterol storage disorders. J Biol Chem 2012;287:39349–39360.
50. Pineda M, Perez-Poyato MS. Current and future therapies for Niemann-Pick C disease. Exp Opin Orphan Drugs 2013;1:915–923.
51. Hasson SA, Kane LA, Yamano K et al. High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy. Nature 2013;504:291–295.
52. Kondo T, Asai M, Tsukita K et al. Modeling Alzheimer’s disease with iPSCs reveals stress phenotypes associated with intracellular Ab and differential drug responsiveness. Cell Stem Cell 2013;12:487–496.
53. Söderberg M, Edlund C, Kristensson K et al. Fatty acid composition of brain phospho-lipids in aging and in Alzheimer’s disease. Lipids 1991;26:421–425.
54. Prasad MR, Lovell MA, Yatin M et al. Regional membrane phospholipid alterations in Alzheimer’s disease. Neurochem Res 1998;23: 81–88.
55. Suzuki H, Park SJ, Tamura M et al. Effect of the long-term feeding of dietary lipids on the learning ability, fatty acid composition of brain stem phospholipids and synaptic membrane fluidity in adult mice: A comparison of sardine oil diet with palm oil diet. Mech Ageing Dev 1998;101:119–128.
56. Kyle DJ, Schaefer E, Patton G et al. Low serum docosahexaenoic acid is a significant risk factor for Alzheimer’s dementia. Lipids 1999;34 (suppl):S245.
57. Gamoh S, Hashimoto M, Hossain S et al. Chronic administration of docosahexaenoic acid improves the performance of radial arm maze taskinaged rats. Clin Exp Pharmacol Phys-iol 2001;28:266–270.
58. Ikemoto A, Ohishi M, Sato Y et al. Reversibility of n-3 fatty acid deficiency-induced alterations of learning behavior in the rat: Level of n-6 fatty acids as another critical factor. J Lipid Res 2001;42:1655–1663.
59. Catalan J, Moriguchi T, Slotnick B et al. Cognitive deficits in docosahexaenoic acid-deficient rats. Behav Neurosci 2002;116:1022–1031.
60. Yagi T, Kosakai A, Ito D et al. Establishment of induced pluripotent stem cells from centenarians for neurodegenerative disease research. PLoS One 2012;7:e41572.
61. Cardno AG, Marshall EJ, Coid B et al. Her-itability estimates for psychotic disorders: The Maudsley twin psychosis series. Arch Gen Psychiatry 1999;56:162–168.
62. Brennand KJ, Simone A, Jou J et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011; 473:221–225.
63. Chiang CH, Su Y, Wen Z et al. Integration-free induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation. Mol Psychiatry 2011;16:358–360.
64. Morrison B III., Saatman KE, Meaney DF et al. In vitro central nervous system models of mechanically induced trauma: A review. J Neurotrauma 1998;15:911–928.
65. Lafaille FG, Pessach IM, Zhang SY et al. Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature 2012;491:769–773.
66. Lee EX, Lam DH, Wu C et al. Glioma gene therapy using induced pluripotent stem cell derived neural stem cells. Mol Pharm 2011;8: 1515–1524.
67. Zhu H, Lensch MW, Cahan P et al. Investigating monogenic and complex diseases with pluripotent stem cells. Nat Rev Genet 2011;12: 266–275.